Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

5
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
5
Dementia l: Introduction01:22

Dementia l: Introduction

12
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
12
Negative and Cognitive Symptoms of Schizophrenia01:30

Negative and Cognitive Symptoms of Schizophrenia

1.1K
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
1.1K
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

906
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
906
Language and Cognition01:27

Language and Cognition

865
Language serves as a bridge between ideas and communication, influencing how individuals perceive and interact with the world. Psychologists have long debated whether language shapes thought or vice versa. This discussion gained grip with Edward Sapir and Benjamin Lee Whorf in the 1940s, who proposed that language determines thought, a concept known as linguistic determinism. They suggested that the vocabulary and structure of a language influence how its speakers think and perceive reality.
865
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

10
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
10

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond dissemination criteria: lesion-based longitudinal MRI of atypical demyelinating lesions at the boundary of multiple sclerosis.

Journal of neurology·2026
Same author

Long-term effectiveness and safety of satralizumab for neuromyelitis optica spectrum disorder in a real-world clinical setting in Japan: A 2.5-year final analysis of a multicenter medical chart review (The SAkuraBeyond Study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

A multicenter, retrospective study in patients with multiple sclerosis treated with natalizumab in a real-world setting in Japan: The REFIND study.

Multiple sclerosis and related disorders·2026
Same author

[Symptoms and Signs of Multiple Sclerosis: Beyond Charcot's Triad].

Brain and nerve = Shinkei kenkyu no shinpo·2025
Same author

B cell depletion as a therapeutic strategy for neuromyelitis optica spectrum disorder: rationale, evidence, and challenges.

Frontiers in immunology·2025
Same author

CD21lo B-cell subsets are recruited to the central nervous system in acute neuromyelitis optica.

Brain : a journal of neurology·2025

Related Experiment Video

Updated: Apr 22, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K

[Cognitive impairment in multiple sclerosis].

Hirofumi Ochi1

  • 1Department of Geriatric Medicine and Neurology, Ehime University Graduate School of Medicine.

Brain and Nerve = Shinkei Kenkyu No Shinpo
|October 10, 2014
PubMed
Summary

Cognitive impairment affects up to 70% of multiple sclerosis (MS) patients, impacting attention, processing speed, and memory. Early diagnosis and understanding disease mechanisms are crucial for comprehensive treatment strategies.

Area of Science:

  • Neurology
  • Neuroimmunology
  • Cognitive Neuroscience

Context:

  • Multiple Sclerosis (MS) is a chronic neurological disease affecting the central nervous system.
  • Cognitive impairment is a prevalent and often early symptom in MS patients, affecting a significant majority.
  • Specific cognitive domains frequently impacted include attention, information processing speed, and working memory.

Purpose:

  • To review the patterns and correlations of cognitive impairment in multiple sclerosis.
  • To highlight neuroimaging biomarkers for predicting cognitive decline in MS.
  • To discuss current treatment avenues and the need for integrated therapeutic strategies.

Summary:

  • Cognitive deficits in MS, particularly in attention, processing speed, and working memory, occur independently of physical disability.

More Related Videos

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.0K

Related Experiment Videos

Last Updated: Apr 22, 2026

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.9K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.4K
Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines
09:46

Rat Model of Widespread Cerebral Cortical Demyelination Induced by an Intracerebral Injection of Pro-Inflammatory Cytokines

Published on: September 21, 2021

5.0K
  • Brain lesion volume, atrophy, and specific neuroimaging markers like diffusion tensor imaging (DTI) correlate with cognitive impairment.
  • Current treatments include disease-modifying therapies, symptomatic management, and cognitive rehabilitation, though intervention data is limited.

    • Impact:

    • Cognitive dysfunction significantly impacts patients' quality of life, employment, and social engagement.
    • Identifying at-risk patients through neuroimaging can facilitate early intervention.
    • A deeper understanding of MS cognitive dysfunction is essential for developing comprehensive, early-stage treatment strategies.